Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Anette, Weyergang"'
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
Externí odkaz:
https://doaj.org/article/21a97d5dc6f24283a4a364fd4fcbc0e3
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundImmune-checkpoint inhibitors (ICIs) represent a revolution in cancer therapy and are currently implemented as standard therapy within several cancer indications. Nevertheless, the treatment is only effective in a subset of patients, and imm
Externí odkaz:
https://doaj.org/article/136fb35175764ba49ca3ac2337f83163
Autor:
Olav Engebraaten, Christina Yau, Kristian Berg, Elin Borgen, Øystein Garred, Maria E. B. Berstad, Ane S. V. Fremstedal, Angela DeMichele, Laura van ’t Veer, Laura Esserman, Anette Weyergang
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Antibody Drug Conjugates (ADCs) are emerging in the field of precision cancer medicine. Here, the authors suggest using endocytosis as a predictive biomarker for response
Externí odkaz:
https://doaj.org/article/e22471ff5b0c4bbbb30060d2218ab799
Publikováno v:
Toxins, Vol 12, Iss 8, p 519 (2020)
Advances in recombinant DNA technology have opened up new possibilities of exploiting toxic proteins for therapeutic purposes. Bringing forth these protein toxins from the bench to the bedside strongly depends on the availability of production method
Externí odkaz:
https://doaj.org/article/59ebbf0a44e94a379f7e91c730368eee
Autor:
Laura van 't Veer, Laura J. Esserman, Øystein Garred, Olav Engebraaten, Maria E B Berstad, Christina Yau, Elin Borgen, Anette Weyergang, Ane Sofie Viset Fremstedal, Angela DeMichele, Kristian Berg
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Nature Communications
Nature communications, vol 12, iss 1
Nature Communications
Nature communications, vol 12, iss 1
HER2 is a predictive biomarker for HER2-targeted therapeutics. For antibody–drug conjugates (ADCs; e.g., trastuzumab emtansine (T-DM1)), HER2 is utilized as a transport gate for cytotoxic agents into the cell. ADC biomarkers may therefore be more c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::772e45a2f0de058ceab0fc1897c8a893
https://doaj.org/article/e22471ff5b0c4bbbb30060d2218ab799
https://doaj.org/article/e22471ff5b0c4bbbb30060d2218ab799
Publikováno v:
Cancer Research. 83:P5-02
Antibody-drug conjugates (ADCs) have demonstrated impressive activity in recent clinical trials in breast cancer. Such targeted therapeutics strongly depends on the presence of target molecules on the tumor cells, and the presence of such target mole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::950f2dd6b64732f299f171721fd657dd
https://doi.org/10.1158/1538-7445.sabcs22-p5-02-21
https://doi.org/10.1158/1538-7445.sabcs22-p5-02-21
Autor:
AM DeMichele, Anette Weyergang, Ane Sofie Viset Fremstedal, Olav Engebråten, Kristian Berg, Øystein Garred, Christina Yau, Elin Borgen, Maria Eb Berstad, L. vant`t Veer, LJ Esserman
PURPOSETargeted therapeutics strongly depends on validated biomarkers in order to select patients most likely to benefit from the treatment. HER2 serves as a predictive biomarker for HER2-targeted tyrosine kinase inhibitors and monoclonal antibodies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19a7feab317450548381f21392cd3aaa
https://doi.org/10.1101/2021.07.06.21255069
https://doi.org/10.1101/2021.07.06.21255069
Publikováno v:
Toxins
Volume 12
Issue 8
Toxins, Vol 12, Iss 519, p 519 (2020)
Volume 12
Issue 8
Toxins, Vol 12, Iss 519, p 519 (2020)
Advances in recombinant DNA technology have opened up new possibilities of exploiting toxic proteins for therapeutic purposes. Bringing forth these protein toxins from the bench to the bedside strongly depends on the availability of production method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2df6a59e33c7f6e55be3853dcb770b5
Autor:
Sebastian Patzke, Maria E B Berstad, Pål Kristian Selbo, Vigdis Sørensen, Kristian Berg, Judith Jing Wen Wong, Ane Sofie Viset Fremstedal, Qian Peng, Anette Weyergang
Publikováno v:
Cancers, Vol 12, Iss 2, p 417 (2020)
Cancers
Volume 12
Issue 2
Cancers
Volume 12
Issue 2
Lysosomal accumulation of sunitinib has been suggested as an underlying mechanism of resistance. Here, we investigated if photochemical internalization (PCI), a technology for cytosolic release of drugs entrapped in endosomes and lysosomes, would act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0387947bd30dd924c7b6d68f0359fe27
https://www.mdpi.com/2072-6694/12/2/417
https://www.mdpi.com/2072-6694/12/2/417
Autor:
Kristian Berg, Henry Hirschberg, Pål Kristian Selbo, Zaid Hamdoon, Theodossis A. Theodossiou, Colin Hopper, Anders Høgset, Waseem Jerjes, Anette Weyergang
Publikováno v:
Journal of clinical medicine, vol 9, iss 2
Journal of Clinical Medicine, Vol 9, Iss 2, p 528 (2020)
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 9, Iss 2, p 528 (2020)
Journal of Clinical Medicine
Photochemical internalisation (PCI) is a unique intervention which involves the release of endocytosed macromolecules into the cytoplasmic matrix. PCI is based on the use of photosensitizers placed in endocytic vesicles that, following light activati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dd252f7fbc5bfdb2ab0bbe3b528af0f
https://escholarship.org/uc/item/9zz582t7
https://escholarship.org/uc/item/9zz582t7